Open original FDA record ↗Recall record
- FDA identifier
- Z-0665-2022
- Company in FDA record
- Becton Dickinson & Company
- FDA record creation date
- Feb 23, 2022
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class III
Reason stated in the source
May shed contaminant particles into the urine specimen that may be misidentified as Red Blood Cells when used in conjunction with the Sysmex UF-1000i or UX-2000 Analyzers and lead to false elevations in RBC counts
Source facts
- Action
- BD issued Urgent Medical Device Correction letter via email to Sysmex on January 06, 2022, requesting they inform/distribute to their customers still using a Sysmex UF-1000i or UX-2000 analyzer the notification provided by BD .The scope would include any customers who were shipped Vacutainer LLAD products still using a Sysmex UF-1000i or UX-2000 analyzer. Sysmex issued letter to their customers addressed to the Urinalysis Manager instructs the customer to respond to Sysmex. 1. Sysmex customers should retain a copy of this notification and post near your analyzer as a visual reminder of this potential issue. 2. Complete the Notification Response Form to confirm receipt of this medical device correction. 3. Report any adverse health consequences experienced with the use of this product to BD. Events may also be reported to the FDA's MedWatch Adverse Event Reporting program. 1. BD is updating the IFU for the LLAD products to include a precaution to confirm any abnormal urinalysis results per facility policy/procedure and best practices and that BD Vacutainer LLAD devices are not recommended for use with Sysmex UF-1000i and UX- 2000 analyzers as it may falsely identify contaminant particles as Red Blood Cells. BD will notify Sysmex via follow-up communication when these revisions are completed (anticipated by June 2022). 2. BD continues to investigate the root cause of this issue and will apply corrective actions as appropriate. Sysmex will be notified if any additional actions are required upon completion of the root cause analysis. Product will continue to ship so as not to impact critical patient care.
- Initiated
- 2022-01-06
- Root cause
- Under Investigation by firm
- Distribution
- US Nationwide distribution in the state of IL.
- Recall number
- Z-0665-2022
- Recall status
- Open, Classified
- CDRH record ID
- 191724
- FDA record created
- 2022-02-23
- Recall event number
- 89486